Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Thrombocytosis 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

Cisplatin 5Cetuximab 3Radiotherapy 2Petrolatum 2Nivolumab 2Magnetic Resonance Spectroscopy 2Fluorouracil 2temoporfin 1talazoparib 1ruxolitinib 1peginterferon alfa-2a 1olaparib 1fluoromisonidazole 1fludarabine phosphate 1fludarabine 1decitabine and cedazuridine drug combination 1cemiplimab 1cedazuridine 1atezolizumab 1aldesleukin 1Vorinostat 1Sorafenib 1Radiotherapy, Intensity-Modulated 1Radiation 1Narrow Band Imaging 1Interviews as Topic 1Interleukin-2 1Gefitinib 1Decitabine 1DNA 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Carcinoma, Squamous Cell × ruxolitinib × Clear all
NCT02593929 2017-06-08

Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer

University of Pittsburgh

Phase EARLY_PHASE1 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡